Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Next Generation Internet ETF (ARKW) vs AstraZeneca plc (AZN) Price & Performance

ARK Next Generation Internet ETFTrade
AstraZeneca plcTrade

Price performance (Past 24H)

Key statistics

ARK Next Generation Internet ETF vs AstraZeneca plc — how do they compare? ARK Next Generation Internet ETF trades at $149.98, while AstraZeneca plc trades at $157.61 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while ARK Next Generation Internet ETF pays none, and ARK Next Generation Internet ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

ARKWAZN
Sector
Sector/ThematicHealth
52-Week High
$182.20$209.48
52-Week Low
$114.45$147.06
Market Cap
$248.14B
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Next Generation Internet ETF

ARKW trades at $150.88, up 0.87% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The ETF focuses on next-generation internet companies, though key financial ratios are not disclosed in the provided data. Recent news highlights long-term growth potential in AI and cloud infrastructure, balanced by near-term capital spending headwinds.

The outlook is mixed, with strong technical momentum but fundamental metrics unavailable for valuation. Risks include market skepticism on AI investments and sector volatility. Analyst sentiment is cautious, citing near-term challenges despite long-term positioning in transformative technologies.

AstraZeneca plc

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Next Generation Internet ETF

ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.

Read more on ARKW

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN